help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamberts, S. W.
Right arrow Articles by de Jong, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamberts, S. W.
Right arrow Articles by de Jong, F. H.

Journal of Clinical Endocrinology & Metabolism, Vol 64, 524-530, Copyright © 1987 by Endocrine Society

ARTICLES

The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin- secreting pituitary adenomas in vivo and in vitro

SW Lamberts, T Verleun, R Oosterom, L Hofland, LA van Ginkel, JG Loeber, CC van Vroonhoven, SZ Stefanko and FH de Jong

The characteristics and dynamics of hormone secretion in vivo and in vitro were investigated in six patients with gonadotropin-secreting pituitary adenomas. All six tumors secreted and contained FSH and different combinations of LH, beta-LH, and alpha-subunit. In addition, immunohistochemical examination of the pituitary tumor tissue showed staining with both LH and FSH in three and either LH or FSH in the other three tumors. TRH and GnRH stimulated hormone secretion in vivo and in vitro, and they also increased the hormone content of the cultured tumor cells. Bromocriptine significantly inhibited hormone release and reduced the hormone content of the tumor cells. In vivo, 2.5 mg bromocriptine significantly suppressed plasma hormone levels; the inhibiting effect on alpha-subunit concentrations was in general more marked than that on LH and FSH. We conclude that hormone release by gonadotropin-secreting pituitary adenomas can be stimulated by TRH and GnRH and inhibited by bromocriptine. Most of these tumors synthesize FSH, but there is a wide variation in the production of LH, beta-LH, and alpha-subunits. The sensitivity of hormone release to bromocriptine suggests that chronic therapy with this drug might have a beneficial effect on pituitary tumor size.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, H. L J Tanghe, A.-J. van der Lely, and D. J Kwekkeboom
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
Eur. J. Endocrinol., November 1, 2006; 155(5): 717 - 723.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. L. Asa, M. A. Kelly, D. K. Grandy, and M. J. Low
Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice
Endocrinology, November 1, 1999; 140(11): 5348 - 5355.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Sanno, L. Jin, X. Qian, R. Y. Osamura, B. W. Scheithauer, K. Kovacs, and R. V. Lloyd
Gonadotropin-Releasing Hormone and Gonadotropin-Releasing Hormone Receptor Messenger Ribonucleic Acids Expression in Nontumorous and Neoplastic Pituitaries
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1974 - 1982.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society